Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Fda Acceptance Of Foreign Clinical Trial Data Feb 2009

Webinar_Feb 24, 2009

  • Login to see the comments

Fda Acceptance Of Foreign Clinical Trial Data Feb 2009

  1. 1. <ul><li>A Product Development Services Company </li></ul><ul><li>From Lab to Market Approval </li></ul><ul><li>Regulatory Strategy </li></ul><ul><li>Strategy Implementation </li></ul><ul><li>Pre-Clinical Assays </li></ul><ul><li>Global Clinical Trials </li></ul><ul><li>Global Regulatory Submissions </li></ul><ul><li>Contact: Patrick Burke at [email_address] </li></ul><ul><li>301-528-7000 </li></ul>Amarex Clinical Research Washington DC metro area
  2. 2. <ul><li>Thank you! </li></ul><ul><li>Goal of these Seminars </li></ul><ul><li>Information sharing </li></ul><ul><li>Professional Development </li></ul><ul><li>Networking </li></ul>
  3. 3. FDA Acceptance of Foreign Clinical Trial Data in INDs and NDA/BLA Mukesh Kumar, PhD, RAC Senior Director, Regulatory Affairs Amarex Clinical Research Germantown, MD 20874, USA Tel: 001-240-750-4893 Email: [email_address]
  4. 4. Agenda for this Seminar <ul><li>Legal Aspects </li></ul><ul><ul><li>Current regulations </li></ul></ul><ul><ul><li>History of acceptance </li></ul></ul><ul><li>Practical Aspects </li></ul><ul><ul><li>Regulatory issues </li></ul></ul><ul><ul><li>Logistical issues </li></ul></ul><ul><ul><li>Scientific issues </li></ul></ul><ul><ul><li>Business issues </li></ul></ul>
  5. 5. Kinds of Foreign Clinical Trails <ul><li>IND studies: Studies partially or completed conducted at foreign sites under a US IND </li></ul><ul><ul><li>All US IND rules apply </li></ul></ul><ul><ul><li>Percent split of foreign verses US subjects </li></ul></ul><ul><li>Non-IND Studies: Studies conducted at foreign sites </li></ul><ul><ul><li>Foreign sponsors </li></ul></ul><ul><ul><li>Conditions apply for acceptance </li></ul></ul>
  6. 6. IND Studies <ul><li>Foreign sites for speed and reduced cost </li></ul><ul><ul><li>All non-US sites treated same (?) </li></ul></ul><ul><ul><li>More than 50% of all IND trials have non-US sites </li></ul></ul><ul><ul><li>More than 40% investigators are non-US </li></ul></ul><ul><li>Involve FDA supervision and discussions </li></ul><ul><li>Percent split in study subjects between US and non-US sites </li></ul><ul><ul><li>Early studies: up to 100% at foreign sites </li></ul></ul><ul><ul><li>Pivotal studies: statistically justifiable subject split between US and foreign sites </li></ul></ul><ul><ul><li>Bridging study for extrapolation of results might be needed </li></ul></ul>
  7. 7. Non-IND Studies <ul><li>Foreign manufacturers </li></ul><ul><ul><li>US market not initially intended </li></ul></ul><ul><ul><li>Product invented/discovered outside the US </li></ul></ul><ul><li>Used in support of an IND or NDA/BLA </li></ul><ul><ul><li>Up to 15% of non-IND data </li></ul></ul>
  8. 8. FDA Acceptance of Foreign Clinical Data <ul><li>Legally acceptable so long as the clinical trials meet the following criteria </li></ul><ul><ul><ul><li>Good Clinical Practices (ICH E6) </li></ul></ul></ul><ul><ul><ul><li>Clinical Investigators of recognized Competence </li></ul></ul></ul><ul><ul><ul><li>Valid Scientific Evidence </li></ul></ul></ul><ul><ul><ul><li>Applicable to U.S. Population/Medical Practice </li></ul></ul></ul>21 CFR §312.120 21 CFR § 860.7
  9. 9. Global Clinical Trials Source: Clinicaltrials.gov
  10. 10. Most of FDA-Registered Investigators Are From the Developed Countries Source: Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2006/2007 Total No. of Investigators (~23000) Non-US Investigators 9.6% 3.9% 1.3% 1.5% 1.9%
  11. 11. FDA Guidance Documents <ul><li>June 1998: ICH E5 – Ethnic factors in the acceptability of foreign clinical data </li></ul><ul><ul><li>Sep. 2006: Clarifications and Q&A </li></ul></ul><ul><li>April 2008: Foreign clinical studies not conducted under an IND application </li></ul>
  12. 12. ICH E5: Ethnic Factors <ul><li>Ethnic factors </li></ul><ul><ul><li>Intrinsic: genetic and physiologic </li></ul></ul><ul><ul><li>Extrinsic: cultural and environmental </li></ul></ul><ul><li>An ICH guidance for acceptance of data generated in one region in another </li></ul><ul><ul><li>Avoid duplication of clinical data </li></ul></ul><ul><ul><li>Characterize effect of ethnic factors on safety, efficacy, dosage and dose regimen </li></ul></ul><ul><ul><li>Bridging studies for extrapolation of results </li></ul></ul>
  13. 13. ICH E5: Main Elements <ul><li>Complete clinical package </li></ul><ul><ul><li>Adequate PK, PD, dose response, safety and efficacy </li></ul></ul><ul><ul><li>GCP clinical trials </li></ul></ul><ul><ul><li>Population representative of the new region </li></ul></ul><ul><li>Extrapolation of data to new region </li></ul><ul><ul><li>Sensitivity to ethnic factors </li></ul></ul><ul><ul><li>Bridging data: safety and efficacy </li></ul></ul><ul><ul><ul><li>Sub-set of complete data </li></ul></ul></ul><ul><ul><ul><li>Bridging clinical study </li></ul></ul></ul>
  14. 14. Non-IND Clinical Studies <ul><li>Acceptable if: “Well-designed, well-conducted study conducted in accordance with GCP and FDA ability to audit” </li></ul><ul><ul><li>Proof of GCP compliance </li></ul></ul><ul><ul><li>On site audit of complete data </li></ul></ul><ul><li>Specific clarification and final decisions provided in April 2008 guidance </li></ul>
  15. 15. Acceptance Criteria for non-IND studies <ul><li>GCP as defined in ICH E6 </li></ul><ul><ul><li>Complete data </li></ul></ul><ul><ul><ul><li>Source data </li></ul></ul></ul><ul><ul><ul><li>CRFs </li></ul></ul></ul><ul><ul><ul><li>Quality documents </li></ul></ul></ul><ul><li>Under the law of the region where study conducted </li></ul><ul><ul><li>All regions follow GCP </li></ul></ul><ul><ul><li>Stringent human subject protection </li></ul></ul>
  16. 16. Acceptance Criteria for non-IND studies <ul><li>Specific documents required </li></ul><ul><li>Investigator qualifications </li></ul><ul><li>Description of research facilities </li></ul><ul><li>Detailed protocol and results </li></ul><ul><li>Complete CMC information </li></ul><ul><li>Scientific rationale and statistical justification of results </li></ul><ul><li>Name and address of the IEC </li></ul><ul><li>Summary of IEC decisions </li></ul><ul><li>Description of informed consent process </li></ul><ul><li>Incentives to participants </li></ul><ul><li>Clinical and safety monitoring processes followed </li></ul><ul><li>Investigator training </li></ul>
  17. 17. Practical Issues with using non-US sites in clinical trials <ul><li>Regulatory issues </li></ul><ul><ul><li>Variations in regional regulatory processes </li></ul></ul><ul><ul><li>Non-IND studies with limited data </li></ul></ul><ul><ul><li>IRB and IEC requirements </li></ul></ul><ul><ul><li>All studies are need for safety ( even studies that cannot be used in support of IND/NDA ) </li></ul></ul><ul><ul><li>Final decision of acceptability resides with FDA </li></ul></ul><ul><li>Logistical issues </li></ul><ul><ul><li>Documentation required </li></ul></ul><ul><ul><li>Packaging of information </li></ul></ul><ul><ul><li>Management of sites and investigators </li></ul></ul>
  18. 18. Practical Issues with using non-US sites in clinical trials <ul><li>Scientific issues </li></ul><ul><ul><li>Extrapolation of results minus the bridging studies </li></ul></ul><ul><ul><li>Characterization of ethnic factors </li></ul></ul><ul><ul><li>Percent split of the subjects between US and non-US sites </li></ul></ul><ul><li>Business issues </li></ul><ul><ul><li>Risk of rejection by the FDA </li></ul></ul><ul><ul><li>Ethical and public policy issues </li></ul></ul><ul><ul><li>Public opinion and political environment </li></ul></ul>
  19. 19. Best Options <ul><li>File IND as early as possible </li></ul><ul><ul><li>Foreign proof-of-concept under US IND </li></ul></ul><ul><ul><li>Good rationale and statistical strength of data </li></ul></ul><ul><li>Strict enforcement of GCP </li></ul><ul><li>Good documentation </li></ul><ul><ul><li>in English – translate early </li></ul></ul><ul><li>FDA discussions </li></ul><ul><ul><li>FDA Meetings and other communications </li></ul></ul><ul><ul><li>Small business office </li></ul></ul><ul><ul><li>Foreign collaboration office </li></ul></ul>
  20. 20. <ul><li>&quot;It takes 20 years to build a reputation and five minutes to ruin it.&quot; </li></ul><ul><li>Warren Buffett Investor, businessman and philanthropist </li></ul>
  21. 21. Thank You! Questions and Comments Mukesh Kumar, PhD, RAC Senior Director, Regulatory Affairs Amarex Clinical Research Germantown, MD 20874, USA Tel: 001-240-750-4893 Email: [email_address]

×